Moderate central vision loss in men (90% of these cases are men) aged 40 to 60 is sometimes caused by central serous retinopathy. Central serous retinopathy is caused by excessively leaky blood vessels in the choroid which is the layer of blood vessels under the retina. When these vessels become excessively leaky, fluid builds up in the choroid and some of that fluid can break through the barrier of the retinal pigment epithelium. The retinal pigment epithelium is a single layer of cells under that retina that are water tight. The fluid that breaks through the retinal pigment epithelium builds up under the retina forming a blister of fluid under the retina. This fluid blurs the vision in two ways. First, because the retina is elevated away from the retinal pigment epithelium by the fluid, it does not receive nutrients and oxygen as efficiently as it should and it doesn’t work well. Second, because the retina is not where it should be, images become out of focus. Some people with central serous retinopathy will notice if they wear reading glasses, they can see better because the reading glasses can sometimes refocus the image on the elevated retina.
The animated image shows a classic smokestack on fluorescein angiography in a patient with acute central serous retinopathy. The white trace dye, fluorescein, does not leak out of the pigment epithelium under the retina. In patients with central serous retinopathy, there is leakage in the choroid of fluid that builds up and then pushes through the barrier layer under the retina, the retina pigment epithelium. That shows up as a leaky spot on the fluorescein angiogram. Because of the concentration gradient in the subretinal fluid, the fluorescein dye moves up from the leaky spot and forms a smokestack looking white are under the center of the macula.
There are several tests that can be done to establish the diagnosis of central serous retinopathy and to help guide management. Fundus autofluorescence – in the accompanying photograph, show the area of bright autofluorescence from the serous retinal detachment. The photoreceptor outer segments that accumulate in the serous retinal detachment autofluoresce and show up bright in the image. Also optical coherence tomography can show the choroidal thickening and the subretinal fluid. Fluorescein angiography and indocyaning green angiography will show which areas of the choroid are leaking and can help guide treatment.
Central serous retinopathy is associated with Type A personality. Ninety percent of cases occur in men. It is also sometimes seen in people taking steroids orally or by nasal spray. It can also be associated with pregnancy. Serous retinal detachments like those seen in central serous retinopathy can also seen in patients with severe high blood pressure, age related macular degeneration, and posterior uveitis.
The diagnosis of central serous retinopathy is usually established with optical coherence tomography, fluorescein angiography, and sometimes indocyanine green angiography.
Visual acuity usually returns to normal within about 6 months (sometimes sooner) in 95 percent of affected patients. The recurrence rate is 25 percent. If vision does not recover in a reasonably amount of time, hot laser, photodynamic therapy (cold laser) can be considered.
There are some patient who develop chronic central serous retinopathy. Those patients have subretinal fluid for more than 6 months. Sometimes subretinal fluid will persist for years. In those situations, the chronic subretinal fluid causes damage to the pigment epithelium and the overlying retina. Vision loss gradually develops. When a patient is treated for chronic subretinal fluid, even when the fluid goes away, there is often residual vision loss. Sometimes, with treatment, the vision loss can be stabilized or slowed. The accompanying image shows gutters where the chronic subretinal fluid tracks down due to gravity and causes damage that is visible with testing.
Very few patients with central serous retinopathy require treatment. 90% of patients improve without therapy. Sometimes, central serous retinopathy becomes chronic and causes vision loss that does not improve. Focal laser treatment to the leaking spot is usually effective in patients with CSR. More commonly, photodynamic laser with visudyne is used to treat CSR. Photodynamic laser is a very low power laser which is used to activate the visudyne. The visudyne is infused intravenously over 10 minutes then a 5 minute washout period is observed. Then 86 seconds of laser (low enegery) is used to activate the the drug and seal up the leaky areas in the choroid. This treatment is usually effective. It is likely safer than focal laser but does sometimes need to be repeated.
Heart-rate Variability Correlates to Choroidal Thickness | OPTH Dove Medical Press
When It Comes to Eye Care, AI Couldn’t See Straight Medpage Today
Keeping Track of FGFR Inhibitor AEs Leads to Optimal Outcomes
Effect of Myopia on vessel density in Glaucomatous patients | OPTH
Dove Medical Press
Blog: MicroPulse laser is an effective tool in the battle against CSR
EyePod: Detecting ROP earlier in a non-invasive way Ophthalmology Times
Non age-related macular degeneration (MD): Causes and treatment Medical News Today
What Is Central Serous Retinopathy? Verywell Health
American Diabetes Association presentation highlights innovations … Ophthalmology Times
Early laser treatment beneficial in central serous chorioretinopathy Ophthalmology Times
How to Treat Central Serous Retinopathy Health Central
Incidence of central serous chorioretinopathy (2011–2018): a … British Journal of Ophthalmology
Treatment of central serous chorioretinopathy with topical NSAIDs … Dove Medical Press
Oral Spironolactone versus Conservative Treatment for Non … Dove Medical Press
How does alcohol affect the eyes?
Medical News Today
Ocular side effects of Trametinib and Dabrafenib: a case report … Journal of Ophthalmic Inflammation and Infection
Treating Central Serous Retinopathy: Adjunctive Nutritional … Dynamic Chiropractic
Assessing Effectiveness and Toxicities in Emerging Therapies in … Targeted Oncology
AI may help with estimate of RP progression Modern Retina
COVID-19 associated with a Purtscher-like retinopathy Ophthalmology Times
Subclinical Cushing’s Syndrome May Be a Risk Factor for Eye … Cushing’s Disease News
Evaluating subthreshold laser technique for CSCR patients Ophthalmology Times Europe
Application of artificial intelligence system for screening multiple … British Journal of Ophthalmology
Kala Pharmaceuticals announces FDA acceptance of IND … Ophthalmology Times
Atypical hemolytic-uremic syndrome: improving outcomes | JMDH
Dove Medical Press
Choroidal involvement in systemic vasculitis: a systematic review … Journal of Ophthalmic Inflammation and Infection
Pregnancy and postpartum ophthalmic changes can present a …
5 diabetes truisms that are (at least partially) false Optometry Times
Ocular associations in pregnancy Insight
Micropulse laser therapy a safe treatment for retinal disorders
Concern over new DVLA notifiable conditions list Optician Online
Researchers unravel why episodes of low blood sugar worsen eye … Ophthalmology Times
January: eye-study | News and features University of Bristol
DVLA updates notifiable eye conditions list Association of Optometrists
Pipeline reveals bright future for combating diabetic eye disease Ophthalmology Times
Computer vision syndrome, mask-associated dry eye & more with … American Medical Association
KYS Vision: clinical outcomes of remote physiologic monitoring for …
Eyenuk CEO and founder gives insight into FDA clearance of …
Janssen Data at ASCO GU Support Ambition to Transform …
Johnson & Johnson
Betrayal comes full circle, says a Salt Lake City gang investigator … Salt Lake Tribune
Retinal scans show eyes as a window to track aging Ophthalmology Times